LifeSci Capital Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $42
LifeSci Capital has reiterated its Buy rating on ArriVent BioPharma (AVBP.US) and maintained its price target of $42. This sustained bullish outlook suggests confidence in the company's future performance.
ArriVent BioPharma, Inc. (AVBP) Receives a Buy from Oppenheimer
Oppenheimer analyst Jeff Jones has reiterated a Buy rating on ArriVent BioPharma, Inc. (AVBP) and set a price target of $50.00. Jones, a 5-star analyst, covers the Healthcare sector with a strong track record. The analyst consensus for ArriVent BioPharma, Inc. is a Strong Buy with an average price target of $44.56, despite the company reporting a quarterly GAAP net loss of $35.54 million in its latest earnings release.
ArriVent Reaffirmed at Buy as Lead Asset Nears 2026 Phase 3 Readout; $42 Price Target Maintained
LifeSci Capital analyst Sam Slutsky has reiterated a Buy rating for ArriVent BioPharma, Inc., maintaining a $42 price target. This affirmation is based on the upcoming mid-2026 Phase 3 data readout for firmonertinib in NSCLC, its FDA Breakthrough Therapy Designation, and positive results from a competitor's trial validating the therapeutic approach. The company's cash runway and early-stage ADC pipeline also contribute to the positive outlook.
ArriVent BioPharma (AVBP) files $250M ATM program with Jefferies
ArriVent BioPharma (AVBP) has filed a prospectus supplement announcing an "at the market" (ATM) program to offer up to $250 million of its common stock through Jefferies LLC as a sales agent. The company plans to use the net proceeds to support the development of its lead product candidate, firmonertinib, other pipeline programs, and for general corporate purposes. This offering is expected to result in an illustrative dilution of $19.38 per share for new investors, based on a $29.50 per share price and 45,308,941 shares outstanding as of March 31, 2026.
ArriVent BioPharma Releases Q1 2026 Financial Results
ArriVent BioPharma Inc. reported a narrower net loss for the first quarter of 2026, with a loss of $0.96 per share and a net loss of $43.3 million. This represents a 49.5% improvement year-over-year from Q1 2025's $1.90 per share loss. The company, which focuses on oncology therapeutics, maintains strong analyst confidence despite being in a pre-revenue stage.
Press Release: ArriVent BioPharma Reports First Quarter 2026 Financial Results
This article reports on ArriVent BioPharma's first-quarter 2026 financial results. It briefly mentions that Unity Software also reported its fourth-quarter earnings, with revenue increasing by 35% year-over-year to $609 million, exceeding estimates, while reporting a quarterly loss of 66 cents per share. The full details for ArriVent BioPharma require a login or account creation.
ArriVent BioPharma Updates At-The-Market Equity Offering Program
ArriVent BioPharma has updated its at-the-market equity offering program, allowing it to sell up to $250 million in common stock through Jefferies LLC. This move provides the company with flexible access to capital, potentially strengthening its balance sheet and funding pipeline activities, though it may also lead to dilution for existing shareholders. Currently, analysts rate AVBP as a Buy with a $44.00 price target, while TipRanks' AI Analyst, Spark, assigns a Neutral score due to mixed financial fundamentals despite positive technicals.
Arrivent BioPharma files prospectus supplement for $250 million at-the-market offering
ArriVent BioPharma (NASDAQ:AVBP) has filed a prospectus supplement for an at-the-market (ATM) equity offering program, aiming to raise up to $250 million through the sale of common stock via Jefferies LLC. The company's shares are currently trading at $29.02, reflecting a 47% year-to-date gain, and analysts note the company's strong cash position despite appearing overvalued. This move follows recent positive coverage from BTIG, which initiated a "buy" rating with a $42.00 price target, citing the potential of ArriVent's oncology drug, firmonertinib.
ArriVent BioPharma (NASDAQ: AVBP) adds $250M ATM stock flexibility
ArriVent BioPharma announced an increase in its "at-the-market" (ATM) stock offering program, allowing it to sell up to $250 million in common stock. This is facilitated through Jefferies LLC as the sales agent, under an Open Market Sale Agreement and an existing automatic shelf registration statement on Form S-3ASR. The expanded program provides ArriVent with flexibility to raise capital over time as needed.
ArriVent BioPharma Inc reports results for the quarter ended March 31 - Earnings Summary
ArriVent BioPharma Inc. has reported its earnings for the quarter that ended on March 31. The summary provides an overview of the company's financial performance during this period. The report is published by Reuters and Refinitiv.
ArriVent BioPharma (NASDAQ: AVBP) posts Q1 2026 loss and details oncology pipeline progress
ArriVent BioPharma reported a narrower net loss of $43.3 million in Q1 2026, compared to $64.4 million in the prior year, primarily due to reduced early-stage R&D spending. The company maintained a strong cash position of $326.4 million, sufficient to fund operations for at least 12 months, and made pipeline advancements, including ongoing Phase 3 trials for firmonertinib in NSCLC and a Phase 1 trial for ARR-217. They also raised $54.7 million through an at-the-market equity program and retain access to a $75 million term loan facility.
A Look At ArriVent BioPharma (AVBP) Valuation After FDA IND Clearance For ARR-002
ArriVent BioPharma received FDA clearance for its investigational new drug, ARR-002, a dual-target antibody-drug conjugate for ovarian and endometrial cancers. Despite recent short-term dips, the company has seen strong year-to-date and 1-year returns. The article analyzes ArriVent's valuation using Price-to-Book ratio and Discounted Cash Flow models, suggesting it may be trading at a discount despite appearing expensive relative to the broader biotech industry.
ArriVent BioPharma Inc expected to post a loss of 89 cents a share - Earnings Preview
ArriVent BioPharma Inc (AVBP) is anticipated to report a loss of 89 cents per share, according to this earnings preview. The information was provided by Refinitiv.
FDA clears new dual-target cancer drug for ovarian, endometrial trial
ArriVent (Nasdaq: AVBP) announced that the FDA has cleared its Investigational New Drug (IND) application for ARR-002, a novel tetravalent MUC16/NaPi2b-targeting antibody-drug conjugate (ADC). This clearance allows ArriVent to proceed with a Phase 1 clinical trial, expected to begin in the second half of 2026, focusing on ovarian and endometrial cancers. Preclinical data for ARR-002 showed enhanced dual-target binding, superior efficacy in xenograft models, and a favorable tolerability profile, suggesting its potential to overcome limitations of single-target ADCs.
Liquidity Mapping Around (AVBP) Price Events
This article from Stock Traders Daily discusses liquidity mapping around price events for Arrivent Biopharma Inc. (NASDAQ: AVBP), highlighting weak near-term sentiment but strong long-term projections. It provides AI-generated trading strategies including position trading, momentum breakout, and risk hedging, along with a multi-timeframe signal analysis for support and resistance levels. The report also details how users can access real-time signals, personalized alerts, and institutional-grade analysis for AVBP.
FMR LLC (AVBP) discloses 3.02M shares, 6.8% stake in Arrivent Biopharma
FMR LLC has filed an amended Schedule 13G/A, disclosing a beneficial ownership of 3,016,131.87 shares, representing a 6.8% stake in Arrivent Biopharma Inc. The filing indicates that FMR LLC holds sole dispositive power over these shares, with Abigail P. Johnson also identified as having dispositive power. This amendment serves as a passive investment disclosure, updating previous filings without signifying a transaction.
FY2026 Earnings Estimate for AVBP Issued By Lifesci Capital
Lifesci Capital has adjusted its FY2026 EPS estimate for ArriVent BioPharma (NASDAQ:AVBP) to ($3.96), which is below the Street's consensus of ($3.59). Despite this, the company recently surpassed quarterly EPS estimates, reporting ($0.78) against an estimated ($0.87). Several other analysts have issued "buy" or "strong-buy" ratings, leading to a "Moderate Buy" consensus and a $43.00 price target.
[ARS] ArriVent BioPharma, Inc. SEC Filing
This article announces an SEC filing (Form ARS) by ArriVent BioPharma, Inc. (AVBP) on April 28, 2026. The filing indicates a low impact and neutral sentiment. Key company information, recent news, and other SEC filings for AVBP are also provided.
ArriVent BioPharma (NASDAQ: AVBP) details 2026 virtual meeting, board elections and CEO pay
ArriVent BioPharma will hold its 2026 annual stockholder meeting virtually on June 18, 2026, where stockholders will vote on electing three directors and ratifying PricewaterhouseCoopers LLP as the independent auditor. The proxy statement details executive compensation, including CEO Zhengbin (Bing) Yao's 2025 total compensation of $9.37 million, largely in stock options, and outlines the company's governance structure, including independent directors and share ownership. Key figures provided include outstanding shares, largest holder ownership, and compensation for top executives.
Citi Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Raises Target Price to $45
Citi has reiterated its Buy rating on ArriVent BioPharma (AVBP.US) and increased its price target to $45. This positive outlook suggests confidence in the company's future performance.
Citigroup Increases ArriVent BioPharma (NASDAQ:AVBP) Price Target to $45.00
Citigroup has increased its price target for ArriVent BioPharma (NASDAQ:AVBP) to $45.00 from $33.00, maintaining a "buy" rating and implying a 44.8% upside. Other analysts also have largely positive sentiments, with a MarketBeat consensus of "Moderate Buy" and an average price target of $43.00. ArriVent BioPharma is a clinical-stage biopharmaceutical company focused on developing cancer therapies, and recently reported beating its quarterly EPS estimates while its stock trades near $31.08.
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Given Average Recommendation of "Moderate Buy" by Analysts
Analysts have given ArriVent BioPharma (NASDAQ:AVBP) an average "Moderate Buy" recommendation based on ratings from twelve firms, with an average one-year price target of $41.67. The clinical-stage biopharmaceutical company, which focuses on targeted cancer therapies like Furmonertinib, saw its stock open at $31.00 and has a market capitalization of $1.37 billion. Institutional investors have also adjusted their holdings, with several actively increasing their stakes in the company.
Arrivent Biopharma stock hits 52-week high at $29.56 By Investing.com
Arrivent Biopharma stock (AVBP) has reached a new 52-week high of $29.57, reflecting a significant 64.3% total return over the past year and a 62.02% increase in value in the last 12 months. This growth indicates strong investor confidence, fueled by analyst optimism with price targets up to $50, despite InvestingPro suggesting the stock may be overvalued. The company's progress with its oral EGFR inhibitor firmonertinib, particularly its upcoming Phase 3 readout for non-small cell lung cancer, is a key factor attracting analyst attention and driving its market performance.
Arrivent Biopharma stock hits 52-week high at $29.56 By Investing.com
Arrivent Biopharma (AVBP) stock reached a new 52-week high of $29.57, reflecting a 62.02% increase in value over the last year and a 64.3% total return. Analysts maintain optimistic price targets up to $50, with BTIG initiating coverage with a "buy" rating and Cantor Fitzgerald reiterating an "Overweight" rating, primarily due to the development of firmonertinib for lung cancer. However, InvestingPro analysis suggests the stock might be overvalued at its current level.
ArriVent BioPharma (NASDAQ:AVBP) Hits New 1-Year High - Time to Buy?
ArriVent BioPharma (NASDAQ:AVBP) recently hit a new 52-week high of $29.49, trading with heavy volume. Despite being an unprofitable clinical-stage oncology company with a negative P/E ratio, it holds a "Moderate Buy" average rating from analysts, with several firms raising price targets. Institutional investors have also increased their holdings in the company.
Wall Street analysts think ArriVent BioPharma, Inc. (AVBP) could surge 72.44%: Read this before placing a bet
This article mentions that Wall Street analysts are predicting a potential 72.44% surge for ArriVent BioPharma, Inc. (AVBP). It advises readers to consider this information before making investment decisions. The content further implies the full article would delve into the reasons behind this optimistic forecast.
ArriVent BioPharma (NASDAQ:AVBP) Sets New 12-Month High - Should You Buy?
ArriVent BioPharma (NASDAQ:AVBP) recently reached a new 52-week high of $27.75, trading at $27.25 with significant volume. Analysts have a "Moderate Buy" consensus rating and an average price target of $41.67, with several firms raising their price objectives. The clinical-stage biopharmaceutical company, with a market capitalization of $1.20 billion, reported better-than-expected Q4 earnings and is advancing its lead drug, Furmonertinib, for non-small cell lung cancer.
Guggenheim Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $45
Guggenheim has reiterated its Buy rating on ArriVent BioPharma (AVBP.US) and maintained its target price of $45. This indicates a continued positive outlook from the firm regarding the company's stock performance and future prospects.
Arrivent Biopharma stock hits 52-week high at 27.25 USD By Investing.com
Arrivent Biopharma Inc.'s stock reached a new 52-week high of $27.22 USD, driven by a 43.79% 1-year total return and strong short-term gains. Analysts have revised earnings upwards, though InvestingPro's Fair Value analysis suggests the stock might be overvalued. The company's development of firmonertinib for non-small cell lung cancer is a key focus for investors and analysts.
Wall Street experts predict that ArriVent BioPharma, Inc. (AVBP) may climb by 72.44%. Check this out before making any investment decisions.
ArriVent BioPharma, Inc. (AVBP) has seen its shares rise 6.2% recently, with Wall Street analysts projecting an average short-term price target of $42.92, suggesting a potential 72.4% upside. This optimism is supported by upward revisions in earnings estimates and a Zacks Rank #2 (Buy), indicating strong near-term potential despite general cautions about relying solely on price targets.
A Look At ArriVent BioPharma (AVBP) Valuation As Shares Show Renewed Momentum
ArriVent BioPharma (AVBP) has shown recent stock momentum with share price returns of 2.77% (1 day) and 16.15% (7 days), following a one-year return of 51.58%. Despite its current pre-revenue status, the SWS Discounted Cash Flow model suggests a fair value of $180.06 compared to its current price of $24.89, indicating it might be undervalued. However, the company faces significant clinical trial uncertainty and a current net loss of US$166.308 million.
AVBP Technical Analysis & Stock Price Forecast
This article provides a technical analysis and stock price forecast for ArriVent BioPharma Inc (AVBP), indicating a "Strong Buy" consensus based on various technical indicators and moving averages. It details specific support and resistance levels, momentum indicators like RSI and MACD, and how the stock is performing relative to its 20-day, 60-day, and 200-day moving averages. As of April 2, 2026, AVBP's share price is $24.89, trading above its key moving averages, suggesting a bullish outlook.
Avoiding Lag: Real-Time Signals in (AVBP) Movement
This article provides real-time signals for Arrivent Biopharma Inc. (NASDAQ: AVBP) based on AI models. It highlights a positive near-term sentiment while noting a mid-term weak bias within a long-term strong context. The analysis includes various trading strategies, support/resistance levels across different timeframes, and emphasizes an exceptional risk-reward short setup.
Clear Street Initiates Coverage of ArriVent BioPharma (AVBP) with Buy Recommendation
Clear Street has initiated coverage of ArriVent BioPharma (AVBP) with a Buy recommendation. This suggests a positive outlook from the financial services firm regarding the company's stock performance. Investors tracking AVBP may consider this new analyst coverage as a potential factor in their investment decisions.
Clear Street Initiates Coverage of ArriVent BioPharma (AVBP) with Buy Recommendation
Clear Street has initiated coverage of ArriVent BioPharma (AVBP) with a Buy recommendation. This move suggests a positive outlook on the biopharmaceutical company's prospects. Investors may view this as a signal for potential growth in AVBP's stock.
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Given Consensus Recommendation of "Moderate Buy" by Brokerages
ArriVent BioPharma (NASDAQ:AVBP) has received a "Moderate Buy" consensus recommendation from brokerages, with an average 12-month target price of $41.67. Institutional ownership stands at approximately 9.48%, with increased positions from firms like Infinitum Asset Management and Suvretta Capital. The company recently reported better-than-expected Q1 EPS and is actively developing targeted cancer therapies.
Assessing ArriVent BioPharma (AVBP) Valuation After Recent Share Price Momentum Shift
ArriVent BioPharma (AVBP) has attracted investor attention due to recent trading activity. Despite being a loss-making company with a stated value score of 3 and trading at a large intrinsic discount (88.2% to its estimated fair value of US$181.15), its P/B ratio of 3.1x is higher than the US Biotechs industry average, yet significantly lower than its direct peer set. This suggests a mixed valuation signal, prompting investors to scrutinize underlying data.
ArriVent to present preclinical cancer drug data at AACR 2026
ArriVent BioPharma will present new preclinical data on its proprietary cancer drug, AVB-710, at the American Association for Cancer Research (AACR) annual meeting in 2026. The presentation will detail the in-vitro and in-vivo activities of AVB-710, an investigational antibody-drug conjugate (ADC), offering insights into its potential therapeutic applications. Further details on the presentation will be announced at a later date.
B. Riley Securities Maintains Buy on ArriVent BioPharma, Raises Price Target to $45
B. Riley Securities has reiterated its Buy rating on ArriVent BioPharma (NASDAQ:AVBP) and increased its price target for the company's stock to $45. The article notes that this is a "headline only" analysis, primarily serving as an alert for real-time intelligence used by traders.
ArriVent BioPharma (NASDAQ:AVBP) Upgraded to Strong-Buy at Truist Financial
Truist Financial has upgraded ArriVent BioPharma (NASDAQ:AVBP) to a "strong-buy" rating, contributing to a consensus "Moderate Buy" rating and an average price target of $41.67 among analysts. The clinical-stage oncology biotech, which is developing targeted therapies for NSCLC including Furmonertinib, reported better-than-expected Q4 EPS. Several institutional investors have also recently increased their positions in the company.
ArriVent to present preclinical cancer drug data at AACR 2026
ArriVent Bio revealed it will present preclinical data on its pipeline cancer drugs at the American Association for Cancer Research (AACR) annual meeting in 2026. The presentation will include findings on AVT-001 and AVT-002, highlighting their potential in treating various cancers. This announcement signals ArriVent's progress in oncology drug development.
ArriVent to Present Preclinical Cancer Drug Data at AACR 2026
ArriVent BioPharma Inc. (Nasdaq: AVBP) will present preclinical data for two cancer drug candidates, firmonertinib and ARR-002, at the American Association for Cancer Research Annual Meeting 2026. Firmonertinib, an EGFR inhibitor, showed efficacy against classical and exon 20 insertion EGFR mutations in non-small cell lung cancer, while ARR-002, a dual-target antibody drug conjugate, demonstrated improved tumor response in ovarian and endometrial cancer models compared to single-target therapies. These presentations build on earlier findings and support continued development of both programs.
Is ArriVent BioPharma (AVBP) Offering Value After Recent Share Price Pullback?
This article analyzes ArriVent BioPharma (AVBP) to determine if its current share price of around US$22.86 presents a fair valuation, especially after a recent 5.1% decline over the last week. Using a Discounted Cash Flow (DCF) analysis, the stock appears significantly undervalued by 85.1%, with an estimated intrinsic value of $153.23 per share. However, its Price to Book (P/B) ratio of 3.29x is above the biotech industry average, suggesting it's about right by that metric.
ArriVent BioPharma (AVBP) to showcase firmonertinib and ARR-002 preclinical data at AACR 2026
ArriVent BioPharma (AVBP) announced it will present preclinical data for its EGFR inhibitor firmonertinib and its novel dual-target MUC16/NaPi2b antibody drug conjugate (ADC) ARR-002 at the 2026 AACR Annual Meeting. The firmonertinib presentation will include high-resolution crystal structure data supporting its ongoing Phase 3 study in non-small cell lung cancer, while ARR-002 data will highlight its potential for ovarian and endometrial cancers. These presentations underscore ArriVent's commitment to advancing innovative biopharmaceutical therapeutics in oncology.
ArriVent to present preclinical data on firmonertinib and dual-target ADC ARR-002 at AACR 2026
ArriVent BioPharma (AVBP) announced it will present preclinical data on its drug candidates, firmonertinib and ARR-002, at AACR 2026. Firmonertinib data will cover its high-resolution structure, broad EGFR activity including ex20ins, potent in vitro/in vivo efficacy, and brain penetrance, supporting ongoing global Phase 3 trials. ARR-002, a MUC16/NaPi2b tetravalent ADC, will have its superior in vivo efficacy, dual-target engagement, enhanced internalization, and favorable tolerability described.
ArriVent BioPharma, Inc. $AVBP Shares Sold by Hidden Lake Asset Management LP
Hidden Lake Asset Management LP significantly reduced its stake in ArriVent BioPharma, Inc. (NASDAQ:AVBP) by 48.3% during the third quarter, selling 292,815 shares and now owning 314,036 shares valued at $5,794,000. Despite this sale, other institutional investors like Vanguard Group Inc. and UBS Group AG increased their holdings. The company currently holds a consensus "Moderate Buy" rating from analysts with an average price target of $40.78, and recently reported better-than-expected quarterly earnings.
Anson Funds Management LP Makes New Investment in ArriVent BioPharma, Inc. $AVBP
Anson Funds Management LP has acquired a new stake in ArriVent BioPharma (NASDAQ:AVBP), purchasing 99,887 shares valued at approximately $1.84 million, representing about 0.24% ownership. Other institutional investors have also adjusted their positions, bringing total institutional ownership to around 9.48%. Despite a negative trailing PE, analysts maintain a "Moderate Buy" consensus for AVBP, with an average price target of $40.78.
Suvretta Capital Management LLC Buys 290,664 Shares of ArriVent BioPharma, Inc. $AVBP
Suvretta Capital Management LLC increased its stake in ArriVent BioPharma, Inc. (AVBP) by 8.5%, purchasing an additional 290,664 shares to bring its total holding to 3,703,452 shares, valued at approximately $68.33 million. This makes ArriVent BioPharma the 17th largest position in Suvretta's portfolio, representing about 8.97% of the company's stock. The article also notes positive analyst sentiment with an average "Moderate Buy" rating and a target price of $40.78 for AVBP, following the company's recent beat on quarterly EPS estimates.
ArriVent BioPharma's (AVBP) Buy Rating Reaffirmed at BTIG Research
BTIG Research has reaffirmed a "Buy" rating and a $42.00 price target for ArriVent BioPharma (AVBP), indicating a potential upside of over 70%. The clinical-stage oncology biotech, which is developing Furmonertinib for NSCLC, holds a consensus "Moderate Buy" rating among analysts with an average price target of $40.78. Institutional investors like Vanguard and UBS have also increased their stakes in the company.
Analysts Offer Insights on Healthcare Companies: ArriVent BioPharma, Inc. (AVBP), Chemomab Therapeutics (CMMB) and Reviva Pharmaceuticals Holdings (RVPH)
Three healthcare companies, ArriVent BioPharma, Inc. (AVBP), Chemomab Therapeutics (CMMB), and Reviva Pharmaceuticals Holdings (RVPH), have received bullish sentiments from analysts. LifeSci Capital maintained a Buy rating on ArriVent BioPharma with a $42.00 price target, while Maxim Group analysts maintained Buy ratings for Chemomab Therapeutics and Reviva Pharmaceuticals Holdings with price targets of $5.00 and $1.00, respectively. The consensus for all three companies is either a Strong Buy or Moderate Buy, indicating positive outlooks from the analyst community.
